Related Experiment Videos
Fixed drug eruption due to foscarnet
G M Connolly1, B G Gazzard, D A Hawkins
1Department of Medicine, Westminster Hospital, London.
Genitourinary Medicine
|April 1, 1990
Abstract:
A case of fixed drug eruption (FDE) secondary to foscarnet is reported. This drug has recently become available on a compassionate use basis for treatment of cytomegalovirus (CMV) infection which may cause significant disease in immunosuppressed patients. Foscarnet provides a useful alternative to the only licensed anti-CMV drug currently available, namely ganciclovir (DHPG), as it has a different toxicity profile. In particular, it does not appear to cause bone marrow suppression which is of importance in AIDS patients as many of them are taking concurrent zidovudine.